Centessa Pharmaceuticals Statistics
Total Valuation
CNTA has a market cap or net worth of $6.19 billion. The enterprise value is $6.03 billion.
| Market Cap | 6.19B |
| Enterprise Value | 6.03B |
Important Dates
The last earnings date was Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTA has 154.73 million shares outstanding. The number of shares has increased by 14.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 154.73M |
| Shares Change (YoY) | +14.73% |
| Shares Change (QoQ) | +8.15% |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 58.21% |
| Float | 92.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 12.71 |
| P/TBV Ratio | 12.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.53, with a Debt / Equity ratio of 0.24.
| Current Ratio | 9.53 |
| Quick Ratio | 9.27 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.69 |
Financial Efficiency
Return on equity (ROE) is -57.38% and return on invested capital (ROIC) is -28.90%.
| Return on Equity (ROE) | -57.38% |
| Return on Assets (ROA) | -27.43% |
| Return on Invested Capital (ROIC) | -28.90% |
| Return on Capital Employed (ROCE) | -42.41% |
| Weighted Average Cost of Capital (WACC) | 10.36% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.94M |
| Employee Count | 129 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CNTA has paid $1.27 million in taxes.
| Income Tax | 1.27M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +217.62% in the last 52 weeks. The beta is 1.12, so CNTA's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | +217.62% |
| 50-Day Moving Average | 39.66 |
| 200-Day Moving Average | 28.96 |
| Relative Strength Index (RSI) | 69.13 |
| Average Volume (20 Days) | 1,598,089 |
Short Selling Information
The latest short interest is 2.57 million, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 2.57M |
| Short Previous Month | 2.47M |
| Short % of Shares Out | 1.96% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.18 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -256.69M |
| Pretax Income | -249.37M |
| Net Income | -250.64M |
| EBITDA | -256.35M |
| EBIT | -256.69M |
| Earnings Per Share (EPS) | -$1.78 |
Balance Sheet
The company has $276.59 million in cash and $118.56 million in debt, with a net cash position of $158.03 million or $1.02 per share.
| Cash & Cash Equivalents | 276.59M |
| Total Debt | 118.56M |
| Net Cash | 158.03M |
| Net Cash Per Share | $1.02 |
| Equity (Book Value) | 487.35M |
| Book Value Per Share | 3.15 |
| Working Capital | 312.11M |
Cash Flow
In the last 12 months, operating cash flow was -$208.80 million and capital expenditures -$371,000, giving a free cash flow of -$209.17 million.
| Operating Cash Flow | -208.80M |
| Capital Expenditures | -371,000 |
| Depreciation & Amortization | 343,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -209.17M |
| FCF Per Share | -$1.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.73% |
| Shareholder Yield | -14.73% |
| Earnings Yield | -4.05% |
| FCF Yield | -3.38% |
Analyst Forecast
The average price target for CNTA is $44.17, which is 10.37% higher than the current price. The consensus rating is "Buy".
| Price Target | $44.17 |
| Price Target Difference | 10.37% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 125.06% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CNTA has an Altman Z-Score of 7.55 and a Piotroski F-Score of 1.
| Altman Z-Score | 7.55 |
| Piotroski F-Score | 1 |